Butyrate for Anti-Inflammatory

Research suggests that butyrate, a short-chain fatty acid produced by gut bacteria during fiber fermentation, exerts anti-inflammatory effects through several well-characterized mechanisms, including inhibition of histone deacetylase (HDAC) enzymes, activation of cell-surface receptors such as GPR109A and FFAR2, suppression of inflammatory signaling pathways like NF-κB, and promotion of anti-inflammatory regulatory T cells. The available evidence draws primarily from animal studies, cell culture experiments, and narrative reviews rather than human clinical trials, with findings generally supporting butyrate's role in reducing intestinal inflammation relevant to conditions like inflammatory bowel disease, as well as suggesting broader effects in tissues including the kidneys and eyes. Some mixed findings exist, particularly around the precision of butyrate's gene-regulatory effects — one 2025 study found that butyrate increases histone acetylation broadly across the genome rather than at specific targeted sites, complicating earlier assumptions about how selectively it controls gene expression — and its relationship with metabolic conditions like obesity remains incompletely understood. Overall, the body of evidence is mechanistically rich and directionally consistent in supporting an anti-inflammatory role for butyrate, but the relative scarcity of controlled human trials means that translating these findings to clinical recommendations requires caution.